logo
Share SHARE
FONT-SIZE Plus   Neg

Boehringer Ingelheim, Eli Lilly Submit NDA For Empagliflozin - Quick Facts

Boehringer Ingelheim and Eli Lilly and Company (LLY) announced that a New Drug Application for the investigational sodium glucose co-transporter-2 inhibitor empagliflozin was recently submitted to the FDA for the treatment of type 2 diabetes mellitus in adults.

Empagliflozin is a member of the SGLT2 inhibitor class of drugs being investigated for the reduction of blood glucose levels in adults with T2D. The emerging SGLT2 inhibitor class removes excess glucose through the urine by blocking glucose re-absorption in the kidney.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Apple has upgraded the data storage option for its online storage service iCloud Drive, now offering 2 terabytes of space for $19.99 a month. The move reportedly indicates a new storage tier for the upcoming iPhone 7, which is set to be launched on September 7, along with the larger iPhone 7 Plus. Shares of Karyopharm Therapeutics Inc. (KPTI) soared over 36% on Tuesday after the company said it will provide an overview of top-line results from its Phase 2b study for oral Selinexor in multiple myeloma, dubbed STORM, on September 6, 2016. Chipotle Mexican Grill (CMG) is giving away free food and drinks this September as the restaurant chain still struggles to boost its sales that has been sluggish after outbreaks of E.coli, salmonella and norovirus at its restaurants. The chain is offering free kids meals every Sunday in September...
comments powered by Disqus
Follow RTT